Aglycosylated full-length IgG antibodies

Steps toward next-generation immunotherapeutics

Man Seok Ju, Sang Taek Jung

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.

Original languageEnglish
Pages (from-to)128-139
Number of pages12
JournalCurrent Opinion in Biotechnology
Volume30
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Antibodies
Immunoglobulin G
Polysaccharides
Cell Engineering
Pharmacokinetics
Antigens
Conformations
Ligands
Cells
Economics
Clinical Trials
Temperature

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Aglycosylated full-length IgG antibodies : Steps toward next-generation immunotherapeutics. / Ju, Man Seok; Jung, Sang Taek.

In: Current Opinion in Biotechnology, Vol. 30, 01.01.2014, p. 128-139.

Research output: Contribution to journalReview article

@article{f6ce85a7339b442cbdea2a8bbbac9868,
title = "Aglycosylated full-length IgG antibodies: Steps toward next-generation immunotherapeutics",
abstract = "Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.",
author = "Ju, {Man Seok} and Jung, {Sang Taek}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.copbio.2014.06.013",
language = "English",
volume = "30",
pages = "128--139",
journal = "Current Opinion in Biotechnology",
issn = "0958-1669",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Aglycosylated full-length IgG antibodies

T2 - Steps toward next-generation immunotherapeutics

AU - Ju, Man Seok

AU - Jung, Sang Taek

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.

AB - Albeit the removal of Asn297 glycans of IgG perturbs the overall conformation and flexibility of the IgG CH2 domain, resulting in the loss of Fc-ligand interactions and therapeutically critical immune effector functions, aglycosylated full-length IgG antibodies are nearly identical to the glycosylated counterparts in terms of antigen binding, stability at physiological or low temperature conditions, pharmacokinetics, and biodistribution. To bypass the drawbacks of glycosylated antibodies that include glycan heterogeneity and requirement of high capital investment for biomanufacturing, aglycosylated antibodies have been developed and several are under clinical trials. Comprehensive cellular and bioprocess engineering has enabled to produce highly complex aglycosylated IgGs in a simple bacterial cultivation with comparable production level as that of mammalian cells. Moreover, extensive engineering of aglycosylated Fc has converted the aglycosylated IgG antibodies into a new class of effector functional human immunotherapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84904344421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904344421&partnerID=8YFLogxK

U2 - 10.1016/j.copbio.2014.06.013

DO - 10.1016/j.copbio.2014.06.013

M3 - Review article

VL - 30

SP - 128

EP - 139

JO - Current Opinion in Biotechnology

JF - Current Opinion in Biotechnology

SN - 0958-1669

ER -